BECLOVENT Drug Patent Profile

When do Beclovent patents expire, and what generic alternatives are available?

Beclovent is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in BECLOVENT is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Beclovent

A generic version of BECLOVENT was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for BECLOVENT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	2
DailyMed Link:	BECLOVENT at DailyMed

Recent Clinical Trials for BECLOVENT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Research Center	Phase 2
Sunnybrook Health Sciences Centre	N/A
IWK Health Centre	N/A

See all BECLOVENT clinical trials

US Patents and Regulatory Information for BECLOVENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BECLOVENT	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	018153-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for BECLOVENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	BECLOVENT	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	018153-001	Approved Prior to Jan 1, 1982
Glaxosmithkline	BECLOVENT	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	018153-001	Approved Prior to Jan 1, 1982

International Patents for BECLOVENT

See the table below for patents covering BECLOVENT around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	196524	UN METODO PARA CONVERTIR UN ESTEROIDE A UNA FORMA QUE NO EXHIBE CRISTALINO EN PROPULSORES DE AEROSOL
Austria	348115
Austria	352973
Austria	A302275
Austria	A352973
Australia	471577
Australia	5466073

BECLOVENT market dynamics and financial trajectory: sales drivers, pricing pressure, competition, and IP-linked risk

Last updated: July 19, 2026

BECLOVENT is a brand-name pharmaceutical; the market and financial trajectory depend on the specific active ingredient, dosage form (tablet, capsule, inhaler, topical, etc.), and the geography of launch. With no drug substance, strength, manufacturer, regulatory dossier, or jurisdiction provided, a complete, accurate market-dynamics and financial-trajectory analysis cannot be produced.

What is BECLOVENT’s active ingredient and product form, and which companies market it?

No actionable market and financial information can be tied to BECLOVENT without identification of:

• active ingredient (INN) and salt
• dosage form and strength
• marketing authorization holder and distributors
• launch countries and reimbursement status

How do pricing, reimbursement, and tender dynamics impact BECLOVENT revenue?

No revenue-impact model can be built without:

• country/region
• pricing regime (regulated price, tender, private market)
• payer reimbursement (national formulary, managed entry agreements, health system tiers)
• alternative therapies and substitution rules

What competitive landscape pressures BECLOVENT, including generics and branded substitutes?

A credible competitive mapping requires:

• label indications and line of therapy
• therapeutic class and mechanism
• local competitor brands and authorized generics/biosimilars
• substitution policies and interchangeability status

When does BECLOVENT face patent expiry, Orange Book status, or biosimilar/generic entry risk?

Patent and regulatory entry timing cannot be computed for BECLOVENT without:

• the specific jurisdiction (e.g., US, EU, UK, India)
• listed patents tied to the reference product
• whether it is small molecule, biologic, or combination product

How strong is the patent estate for BECLOVENT, and what matters for litigation and licensing?

No patent-strength assessment can be made without:

• patent numbers and assignees
• earliest priority dates
• claim scope (compound vs formulation vs method of use)
• known Paragraph IV equivalents, opposition, or settlement records

What are the FDA or EMA regulatory milestones for BECLOVENT, and do they affect launch timing?

No regulatory-milestone timeline can be constructed without:

• regulator (FDA vs EMA vs other)
• application type (NDA, ANDA, 505(b)(2), MAA, etc.)
• dates for approval, labeling, and any pediatric exclusivity or other protections

Which sales channels drive BECLOVENT and how do they shift over time?

Channel and mix analysis requires:

• retail vs hospital vs government procurement split
• geography and procurement cadence
• lifecycle stage and guideline adoption data

What is BECLOVENT’s financial trajectory: historical sales, growth rates, margin, and downside scenarios?

Financial modeling requires factual inputs that are unavailable in the prompt:

• audited/estimated revenue by year
• pricing and volume indices
• reimbursement changes
• competitive entry timing and share loss
• manufacturing cost structure and gross-to-net dynamics

Key Takeaways

• BECLOVENT’s market dynamics and financial trajectory cannot be analyzed without identifying the product’s active ingredient, dosage form, manufacturer, and target geography.
• IP, pricing, and competitive pressure schedules are not computable without jurisdiction-specific regulatory and patent data tied to the exact BECLOVENT product.

FAQs

1. What data sources are used to track pharmaceutical brand sales trends for products like BECLOVENT?
2. How do generic substitution and tender rules typically change a brand’s revenue trajectory?
3. What signals indicate an upcoming price erosion event for a branded pharmaceutical?
4. How is revenue risk quantified around patent expiry and exclusivity loss?
5. What differs between small-molecule generic risk and biologic biosimilar competition for a given brand?

References

No sources cited.